FDA Rejects Summit Therapeutics' China-Made Lung Cancer Drug
The FDA has turned down ivonescimab, a lung cancer drug developed in China that Summit Therapeutics sought to bring to the U.S. market.
The U.S. Food and Drug Administration has rejected ivonescimab, a lung cancer treatment invented in China that Florida-based Summit Therapeutics had been working to introduce to the American market, according to a report from The New York Times.
The decision marks a significant setback for Summit Therapeutics, which had positioned ivonescimab as a closely watched candidate in the competitive landscape of oncology therapeutics. The drug had drawn considerable attention from investors and medical observers tracking the pipeline of cancer treatments moving through regulatory review.
Read more Ralph Lauren's Turnaround Is Led by a French CEO →
Ivonescimab represents part of a broader trend of pharmaceutical companies seeking to license or commercialize drugs originally developed in China for Western markets. The FDA's rejection raises questions about the regulatory pathway for such drugs and what additional data or clinical trial design changes may be required to satisfy U.S. standards.
Lung cancer remains one of the leading causes of cancer-related deaths in the United States, sustaining strong demand for new and more effective therapies. The rejection does not necessarily foreclose future attempts to seek approval, as companies often resubmit applications following additional clinical work or in response to specific agency feedback.
Continue reading at NYT > Business